Table 1 Baseline Characteristics of Pazopanib Recipients in the PALETTE Trial (ITT Population)
|
Pazopanib Arm (n = 246) | |
|---|---|
| Age, y, mean (SD) | 54.0 (14.9) |
| < 65 y, n (%) | 184 (75) |
| ≥65 y, n (%) | 62 (25) |
| Female, n (%) | 147 (60) |
| Weight, kg, mean (SD) | 71.5 (16.9) |
| STS subtypes, n (%) | |
| Leiomyosarcoma | 109 (44) |
| Synovial sarcoma | 25 (10) |
| Other STS histologies | 112 (46) |
| Time since initial diagnosis, mo, median (IQR) | 26.6 (14.5–46.1) |
| Time since last progression, mo, median (IQR) | 0.7 (0.3–1.1) |
| Prior lines of therapy, n (%) | |
| 1 | 110 (45) |
| 2 or more | 136 (55) |
